CN101484470B - 具有增强的抗体依赖性细胞毒性活性的抗体及其生产方法和用途 - Google Patents

具有增强的抗体依赖性细胞毒性活性的抗体及其生产方法和用途 Download PDF

Info

Publication number
CN101484470B
CN101484470B CN200680048006.XA CN200680048006A CN101484470B CN 101484470 B CN101484470 B CN 101484470B CN 200680048006 A CN200680048006 A CN 200680048006A CN 101484470 B CN101484470 B CN 101484470B
Authority
CN
China
Prior art keywords
antibody
antibodies
human
milk
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200680048006.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN101484470A (zh
Inventor
丹尼尔·申德勒
哈里·M·米德
蒂莫西·埃德蒙兹
约翰·麦克弗森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
LFB USA Inc
Original Assignee
Genzyme Corp
GTC Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp, GTC Biotherapeutics Inc filed Critical Genzyme Corp
Publication of CN101484470A publication Critical patent/CN101484470A/zh
Application granted granted Critical
Publication of CN101484470B publication Critical patent/CN101484470B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/04—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from milk
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/12—Immunoglobulins specific features characterized by their source of isolation or production isolated from milk
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN200680048006.XA 2005-10-21 2006-10-23 具有增强的抗体依赖性细胞毒性活性的抗体及其生产方法和用途 Expired - Fee Related CN101484470B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US72905405P 2005-10-21 2005-10-21
US60/729,054 2005-10-21
PCT/US2006/041656 WO2007048077A2 (en) 2005-10-21 2006-10-23 Antibodies with enhanced antibody-dependent cellular cytoxicity activity, methods of their production and use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN2013101589165A Division CN103435695A (zh) 2005-10-21 2006-10-23 具有增强的抗体依赖性细胞毒性活性的抗体及其生产方法和用途

Publications (2)

Publication Number Publication Date
CN101484470A CN101484470A (zh) 2009-07-15
CN101484470B true CN101484470B (zh) 2014-07-23

Family

ID=37820635

Family Applications (2)

Application Number Title Priority Date Filing Date
CN200680048006.XA Expired - Fee Related CN101484470B (zh) 2005-10-21 2006-10-23 具有增强的抗体依赖性细胞毒性活性的抗体及其生产方法和用途
CN2013101589165A Pending CN103435695A (zh) 2005-10-21 2006-10-23 具有增强的抗体依赖性细胞毒性活性的抗体及其生产方法和用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2013101589165A Pending CN103435695A (zh) 2005-10-21 2006-10-23 具有增强的抗体依赖性细胞毒性活性的抗体及其生产方法和用途

Country Status (13)

Country Link
US (3) US20080118501A1 (cg-RX-API-DMAC7.html)
EP (3) EP2388272A1 (cg-RX-API-DMAC7.html)
JP (2) JP5328019B2 (cg-RX-API-DMAC7.html)
KR (3) KR20080068089A (cg-RX-API-DMAC7.html)
CN (2) CN101484470B (cg-RX-API-DMAC7.html)
AU (1) AU2006304886B2 (cg-RX-API-DMAC7.html)
CA (1) CA2626542C (cg-RX-API-DMAC7.html)
DK (2) DK2388273T3 (cg-RX-API-DMAC7.html)
ES (2) ES2642787T3 (cg-RX-API-DMAC7.html)
IL (1) IL218943A0 (cg-RX-API-DMAC7.html)
NZ (1) NZ568433A (cg-RX-API-DMAC7.html)
PL (1) PL1945666T3 (cg-RX-API-DMAC7.html)
WO (1) WO2007048077A2 (cg-RX-API-DMAC7.html)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080019905A9 (en) * 2005-02-18 2008-01-24 Strome Scott E Method of using an anti-CD137 antibody as an agent for radioimmunotherapy or radioimmunodetection
KR20080068089A (ko) * 2005-10-21 2008-07-22 지티씨바이오쎄라퓨틱스,인크. 항체 의존성 세포 독성 활성이 증강된 항체, 그 생산 및사용 방법
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
WO2008030564A2 (en) * 2006-09-08 2008-03-13 Verenium Corporation Aglycosylated antibodies and methods of making and using those antibodies
FR2915398B1 (fr) * 2007-04-25 2012-12-28 Lab Francais Du Fractionnement "ensemble de moyens pour le traitement d'une pathologie maligne, d'une maladie auto-immune ou d'une maladie infectieuse"
EP1995309A1 (en) * 2007-05-21 2008-11-26 Vivalis Recombinant protein production in avian EBx® cells
US8647626B2 (en) 2007-10-02 2014-02-11 Avaxia Biologics, Incorporated Compositions comprising TNF-specific antibodies for oral delivery
WO2009046168A1 (en) * 2007-10-02 2009-04-09 Avaxia Biologics, Inc. Antibody therapy for use in the digestive tract
ES2336873B1 (es) * 2007-11-07 2011-01-24 Proyecto De Biomedicina Cima, S.L. Composicion farmaceutica para el tratamiento de cancer.
JP2011512875A (ja) * 2008-03-11 2011-04-28 ジェネンテック， インコーポレイテッド 増強されたａｄｃｃ機能を有する抗体
WO2009124109A1 (en) 2008-04-04 2009-10-08 The Government Of The U.S. A. As Represented By The Secretary Of The Dept. Of Health &Human Services Human monoclonal antibodies specific for cd22
WO2009134389A2 (en) * 2008-05-01 2009-11-05 Gtc Biotherapeutics, Inc. An anti-cd137 antibody as an agent in the treatment of inflammatory conditions
US8084222B2 (en) 2008-09-26 2011-12-27 Eureka Therapeutics, Inc. Methods for generating host cells
US8475790B2 (en) 2008-10-06 2013-07-02 Bristol-Myers Squibb Company Combination of CD137 antibody and CTLA-4 antibody for the treatment of proliferative diseases
TWI409079B (zh) * 2009-08-14 2013-09-21 Roche Glycart Ag 非典型岩藻醣化ｃｄ２０抗體與苯達莫斯汀（ｂｅｎｄａｍｕｓｔｉｎｅ）之組合療法
SG10201510640QA (en) 2009-10-26 2016-01-28 Hoffmann La Roche Method For The Production Of A Glycosylated Immunoglobulin
FR2962908A1 (fr) 2010-07-20 2012-01-27 Lfb Biotechnologies Formulation d'anticorps anti-cd20
CN116585504A (zh) 2010-12-30 2023-08-15 法国化学与生物科技实验室 作为病原体灭活剂的二元醇
FR2976811A1 (fr) 2011-06-22 2012-12-28 Lfb Biotechnologies Utilisation d'un anticorps anti-cd20 a haute adcc pour le traitement de la maladie de waldenstrom
CN103827134A (zh) 2011-07-20 2014-05-28 泽普泰恩股份有限公司 多肽分离方法
EP2741769B1 (en) * 2011-08-10 2019-01-02 Laboratoire Français du Fractionnement et des Biotechnologies Highly galactosylated antibodies
US20130302274A1 (en) * 2011-11-25 2013-11-14 Roche Glycart Ag Combination therapy
WO2013114240A2 (en) * 2012-01-30 2013-08-08 Dr. Reddy's Laboratories Limited Method for obtaining a glycoprotein composition
WO2013114245A1 (en) 2012-01-30 2013-08-08 Dr. Reddy's Laboratories Limited Process of modulating man5 and/or afucosylation content of glycoprotein composition
TW201425332A (zh) 2012-08-03 2014-07-01 Revo Biolog Inc 抗凝血酶用於體外膜氧合之用途
HUE043903T2 (hu) * 2012-12-03 2019-09-30 Bristol Myers Squibb Co Immunmodulációs FC fúziós proteinek rákellenes aktivitásának javítása
EP3514175A1 (fr) 2012-12-17 2019-07-24 Laboratoire Français du Fractionnement et des Biotechnologies Utilisation d'anticorps monoclonaux pour le traitement de l'inflammation et d'infections bacteriennes
BR112015019348A2 (pt) 2013-02-13 2017-08-22 Lab Francais Du Fractionnement Métodos para produção de proteína com glicosilação modificada e com sialilação aumentada, para aumentar a atividade de sialil transferase na glândula mamária e para produzir sialil transferase, proteína com glicosilação modificada ou proteína com sialilação aumentada, composição, sialil transferase, mamífero transgênico, e, célula epitelial mamária
EP3594230A1 (en) * 2013-02-13 2020-01-15 Laboratoire Français du Fractionnement et des Biotechnologies Highly galactosylated anti-tnf-alpha antibodies and uses thereof
WO2014125377A2 (en) * 2013-02-13 2014-08-21 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Highly galactosylated anti-her2 antibodies and uses thereof
CN105358577A (zh) 2013-02-13 2016-02-24 法国化学与生物科技实验室 具有经修饰的糖基化的西妥昔单抗及其用途
WO2014177771A1 (en) 2013-05-02 2014-11-06 Glykos Finland Oy Conjugates of a glycoprotein or a glycan with a toxic payload
TW201509432A (zh) 2013-07-05 2015-03-16 Lab Francais Du Fractionnement 親和層析基質
FR3016633B1 (fr) 2014-01-17 2018-04-13 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Immunoglobuline anti-toxine du charbon
WO2015164723A1 (en) 2014-04-25 2015-10-29 The Trustees Of The University Of Pennsylvania Methods and compositions for treating metastatic breast cancer and other cancers in the brain
FR3025515B1 (fr) 2014-09-05 2016-09-09 Lab Francais Du Fractionnement Procede de purification d'un anticorps monoclonal
FR3034420A1 (fr) 2015-03-31 2016-10-07 Lab Francais Du Fractionnement Anticorps monoclonaux anti-cd303
FR3038517B1 (fr) 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie
CN105886656B (zh) * 2016-06-24 2019-11-12 河北医科大学第四医院 Gif基因在食管鳞癌诊治中的应用
CN106199005B (zh) * 2016-07-26 2019-02-01 浙江大学 采用cd137表达量检测淋巴细胞抗大肠癌活性的方法
CN107987160A (zh) * 2016-10-26 2018-05-04 无锡科捷诺生物科技有限责任公司 一种无岩藻糖基化的单克隆抗体
EP3544601B1 (en) * 2016-11-23 2024-03-20 Translational Drug Development, LLC A composition comprising a benzamide and a tnfrsf agonist binding to 4-1bb or gitr, and the use thereof in the treatment of cancer.
FR3060394B1 (fr) 2016-12-16 2019-05-24 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Combinaison d'anticorps anti-cd303 et anti-amhrii
FR3060395B1 (fr) 2016-12-16 2019-05-24 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Combinaison d'anticorps anti-cd303 et anti-her2
CN107083362A (zh) * 2017-06-19 2017-08-22 金浩范 一种自体nk细胞制备方法及实施该方法的试剂盒
EP3498293A1 (en) 2017-12-15 2019-06-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Treatment of monogenic diseases with an anti-cd45rc antibody
FR3076294B1 (fr) 2017-12-29 2022-01-28 Lab Francais Du Fractionnement Procede de purification d'anticorps a partir de lait brut
US20210221908A1 (en) 2018-06-03 2021-07-22 Lamkap Bio Beta Ltd. Bispecific antibodies against ceacam5 and cd47
EP3626265A1 (en) 2018-09-21 2020-03-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-human cd45rc antibodies and uses thereof
TWI839395B (zh) * 2018-10-09 2024-04-21 瑞士商Ｎｕｍａｂ治療公司 靶向cd137的抗體及其使用方法
EP3636320A1 (en) * 2018-10-09 2020-04-15 Numab Therapeutics AG Antibodies targeting cd137 and methods of use thereof
BR112021014574A2 (pt) 2019-01-23 2021-10-05 Encefa Competidores cd31 e usos dos mesmos
EP3831849A1 (en) 2019-12-02 2021-06-09 LamKap Bio beta AG Bispecific antibodies against ceacam5 and cd47
PE20231386A1 (es) 2020-12-18 2023-09-12 Lamkap Bio Beta Ltd Anticuerpos biespecificos contra ceacam5 y cd47
CN112724263B (zh) * 2021-04-02 2021-08-03 上海偌妥生物科技有限公司 改造抗cd20单克隆抗体以提高其药物疗效的方法及其应用
CN113648405B (zh) * 2021-08-19 2023-06-02 重庆医科大学 一种口服重组幽门螺杆菌蛋白疫苗纳米粒及其制备方法
CN118369344A (zh) 2021-09-16 2024-07-19 阿博莱斯制药公司 抗人cd45rc结合结构域及其用途
IL313752A (en) 2021-12-20 2024-08-01 Vetoquinol Sa Antibodies against canine interleukin 33 receptor and their uses
WO2023242351A1 (en) 2022-06-16 2023-12-21 Lamkap Bio Beta Ag Combination therapy of bispecific antibodies against ceacam5 and cd47 and bispecific antibodies against ceacam5 and cd3
EP4662240A2 (fr) 2023-02-09 2025-12-17 Commissariat à l'Energie Atomique et aux Energies Alternatives Fragment fab mutant pour l'obtention de conjugués mono- ou bi-fonctionnalisés site-spécifiques
WO2025114614A1 (en) 2023-11-30 2025-06-05 Vetoquinol Sa Anti-canine interleukine-4-receptor alpha (il-4rα) antibodies and the uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004009618A2 (en) * 2002-07-18 2004-01-29 Crucell Holland B.V. Recombinant production of mixtures of antibodies
EP1400171A1 (en) * 1993-12-20 2004-03-24 GTC Biotherapeutics, Inc. Transgenic production of antibodies in milk
WO2004050847A2 (en) * 2002-11-27 2004-06-17 Gtc Biotherapeutics, Inc. Modified antibodies stably produced in milk and methods of producing same
WO2006088464A2 (en) * 2005-02-15 2006-08-24 Gtc Biotherapeutics, Inc. A method of using an anti-cd137 antibody as an agent for radioimmunotherapy or radioimmunodetection

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2459619B1 (fr) * 1979-06-26 1983-07-29 Agronomique Inst Nat Rech Procede pour l'obtention a partir de lactoserum, d'un produit enrichi en alpha-lactalbumine et applications dudit procede
US4257774A (en) * 1979-07-16 1981-03-24 Meloy Laboratories, Inc. Intercalation inhibition assay for compounds that interact with DNA or RNA
US4361544A (en) * 1980-03-03 1982-11-30 Goldenberg Milton David Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3432718C1 (de) * 1984-09-06 1986-05-22 Biotest Pharma GmbH, 6000 Frankfurt Verfahren zur Herstellung einer Loesung von Milch- und/oder Kolostralimmunglobulinen
US5322775A (en) * 1986-06-30 1994-06-21 Pharmaceutical Proteins Ltd. Peptide production
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4873316A (en) * 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5750172A (en) * 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
US5202238A (en) * 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US4897465A (en) * 1988-10-12 1990-01-30 Abbott Laboratories Enrichment and concentration of proteins by ultrafiltration
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US6362325B1 (en) * 1988-11-07 2002-03-26 Advanced Research And Technology Institute, Inc. Murine 4-1BB gene
US20060002904A9 (en) * 1988-11-07 2006-01-05 Kwon Byoung S Receptor and related products and methods
US6355476B1 (en) * 1988-11-07 2002-03-12 Advanced Research And Technologyinc Nucleic acid encoding MIP-1α Lymphokine
US6303121B1 (en) * 1992-07-30 2001-10-16 Advanced Research And Technology Method of using human receptor protein 4-1BB
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5633076A (en) * 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5965789A (en) * 1991-01-11 1999-10-12 American Red Cross Engineering protein posttranslational modification by PACE/furin in transgenic non-human mammals
CA2082951C (en) 1991-03-15 1999-12-21 Robert M. Platz Pulmonary administration of granulocyte colony stimulating factor
US5714350A (en) * 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5674704A (en) * 1993-05-07 1997-10-07 Immunex Corporation Cytokine designated 4-IBB ligand
US7211259B1 (en) * 1993-05-07 2007-05-01 Immunex Corporation 4-1BB polypeptides and DNA encoding 4-1BB polypeptides
US7138500B1 (en) * 1993-05-07 2006-11-21 Immunex Corporation Antibodies to human 4-1BB
US5824837A (en) * 1993-07-22 1998-10-20 Merck & Co., Inc. Expression of human interleukin-1β in a transgenic animal
CA2172165C (en) * 1993-09-16 2003-12-02 Byoung S. Kwon Human receptor h4-1bb
EP0750671A1 (en) * 1994-03-09 1997-01-02 Abbott Laboratories Transgenic animals producing oligosaccharides and glycoconjugates
JPH09512705A (ja) * 1994-03-29 1997-12-22 セルテック セラピューティクス リミテッド Ｅ−セレクチンに対する抗体
US5451569A (en) 1994-04-19 1995-09-19 Hong Kong University Of Science And Technology R & D Corporation Limited Pulmonary drug delivery system
EP0690452A3 (en) 1994-06-28 1999-01-07 Advanced Micro Devices, Inc. Electrically erasable memory and method of erasure
KR100270650B1 (ko) * 1994-12-23 2000-11-01 돈 리사 로얄 돌연변이된 숙주효소를 이용한 항체-지시된 효소 전구약제 치료
PT766745E (pt) * 1995-04-08 2003-02-28 Lg Chemical Ltd ANTICORPO MONOCLONAL ESPECíFICO PARA 4-1BB HUMANO E LINHA CELULAR PARA PRODUCAO DO MESMO
US6998467B1 (en) 1995-04-28 2006-02-14 The Hospital For Sick Children Antibody specific for presenilin 1 and method of use thereof
US5874240A (en) * 1996-03-15 1999-02-23 Human Genome Sciences, Inc. Human 4-1BB receptor splicing variant
US6268487B1 (en) * 1996-05-13 2001-07-31 Genzyme Transgenics Corporation Purification of biologically active peptides from milk
DE69718268D1 (de) * 1996-10-03 2003-02-13 Canon Kk Verfahren zur Detektion von Zielnukleinsäure, Verfahren zu ihrer Quantifizierung und Pyrylium-Verbindungen zur Chemilumineszenz-Analyse
CN1232402A (zh) * 1996-10-11 1999-10-20 布里斯托尔-迈尔斯斯奎布公司 免疫调节的方法和组合物
US5945577A (en) 1997-01-10 1999-08-31 University Of Massachusetts As Represented By Its Amherst Campus Cloning using donor nuclei from proliferating somatic cells
EP0990001B1 (en) * 1997-05-29 2006-05-10 Agresearch Limited Processes for production of immunoglobulin a in milk
US20030175754A1 (en) 1998-06-29 2003-09-18 Incyte Genomics, Inc. RVP-1 variant differentially expressed in crohns disease
US20030096976A1 (en) * 1998-11-17 2003-05-22 Hong Hyo Jeong Humanized antibodies LB-00503 and LB-00506 specific for human 4-1BB and pharmaceutical compositions comprising said humanized antibodies
KR20000034847A (ko) * 1998-11-17 2000-06-26 성재갑 인간 4-1비비 분자에 대한 인간화 항체 및 이를 포함하는 약학조성물
US7414170B2 (en) * 1999-11-19 2008-08-19 Kirin Beer Kabushiki Kaisha Transgenic bovines capable of human antibody production
AU781544B2 (en) * 2000-02-03 2005-05-26 Lennart Hammarstrom Ruminant MHC class I-like Fc receptors
FR2807767B1 (fr) * 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
US20040247563A1 (en) * 2000-11-02 2004-12-09 Lynch David H. Method of enhancing lymphocyte-mediated immune responses
WO2003006058A1 (en) * 2001-07-12 2003-01-23 Wyeth Cd25+ differential markers and uses thereof
EP1434596B1 (en) * 2001-10-09 2009-07-08 Mayo Foundation For Medical Education And Research Enhancement of immune responses by agonist 4-1bb-antibodies
US7053202B2 (en) * 2001-10-19 2006-05-30 Millennium Pharmaceuticals, Inc. Immunoglobulin DNA cassette molecules, monobody constructs, methods of production, and methods of use therefor
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US20030223989A1 (en) * 2002-04-18 2003-12-04 Pluenneke John D. CD137 agonists to treat patients with IgE-mediated conditions
US20040109847A1 (en) * 2002-07-15 2004-06-10 Lieping Chen Treatment and prophylaxis with 4-1BB-binding agents
EP1539237A4 (en) * 2002-07-30 2006-05-24 Bristol Myers Squibb Co HUMANIZED ANTIBODIES AGAINST HUMAN 4-1BB
US20040025193A1 (en) * 2002-08-01 2004-02-05 Yann Echelard Method for the rapid selection of homozygous primary cell lines for the production of transgenic animals by somatic cell nuclear transfer
US20060121030A1 (en) * 2002-12-16 2006-06-08 Herbert Schwarz Use of cd 137 antagonists for the treatment of tumors
CA2512729C (en) * 2003-01-09 2014-09-16 Macrogenics, Inc. Identification and engineering of antibodies with variant fc regions and methods of using same
US7471635B2 (en) * 2003-07-16 2008-12-30 Qlogic, Corporation Method and apparatus for test pattern generation
EP2502935B1 (en) * 2003-08-22 2017-03-29 Biogen MA Inc. Improved antibodies having altered effector function and methods for making the same
US7288638B2 (en) * 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
US7045295B2 (en) * 2004-04-02 2006-05-16 Hematologics, Inc. Method for collecting purified cells
EP1851244A4 (en) * 2005-02-15 2009-04-15 Gtc Biotherapeutics Inc ANTI-CD137 ANTIBODY AS A MEANS FOR THE TREATMENT OF CANCER, AND GLYCOSYLATION VARIANTS THEREOF
US20080019905A9 (en) * 2005-02-18 2008-01-24 Strome Scott E Method of using an anti-CD137 antibody as an agent for radioimmunotherapy or radioimmunodetection
US20060182744A1 (en) * 2005-02-15 2006-08-17 Strome Scott E Anti-CD137 antibody as an agent in the treatment of cancer and glycosylation variants thereof
EP1937305A4 (en) * 2005-09-09 2008-10-08 Glycofi Inc IMMUNOGLOBULIN CONTAINING PRESENTLY A MAN7GLCNAC2, MAN8GLCNAC2 GLYCOFORM
KR20080068089A (ko) * 2005-10-21 2008-07-22 지티씨바이오쎄라퓨틱스,인크. 항체 의존성 세포 독성 활성이 증강된 항체, 그 생산 및사용 방법
WO2007048122A2 (en) * 2005-10-21 2007-04-26 Genzyme Corporation Antibody-based therapeutics with enhanced adcc activity
WO2009134389A2 (en) * 2008-05-01 2009-11-05 Gtc Biotherapeutics, Inc. An anti-cd137 antibody as an agent in the treatment of inflammatory conditions
US10798205B2 (en) 2016-04-13 2020-10-06 Facebook, Inc. Cache system for live broadcast streaming

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1400171A1 (en) * 1993-12-20 2004-03-24 GTC Biotherapeutics, Inc. Transgenic production of antibodies in milk
WO2004009618A2 (en) * 2002-07-18 2004-01-29 Crucell Holland B.V. Recombinant production of mixtures of antibodies
WO2004050847A2 (en) * 2002-11-27 2004-06-17 Gtc Biotherapeutics, Inc. Modified antibodies stably produced in milk and methods of producing same
WO2006088464A2 (en) * 2005-02-15 2006-08-24 Gtc Biotherapeutics, Inc. A method of using an anti-cd137 antibody as an agent for radioimmunotherapy or radioimmunodetection

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AF Kolb et al.Virus-neutralizing monoclonal antibody expressed in milk of transgenic mice provides full protection againstvirus-induced encephalitis.《journal of virology》.2001,第75卷(第6期),2803-2909. *
Liu A et al.A comparison of herpes simplex virus specific antibodies found in human milk and serum.《Pediatric research》.1992,第31卷(第6期),表1、593页右栏第57-60行. *

Also Published As

Publication number Publication date
US20080118501A1 (en) 2008-05-22
KR20130089673A (ko) 2013-08-12
DK2388273T3 (en) 2017-10-09
EP1945666A2 (en) 2008-07-23
US20140046033A1 (en) 2014-02-13
JP5328019B2 (ja) 2013-10-30
KR101507027B1 (ko) 2015-03-31
EP1945666B1 (en) 2013-03-27
EP2388273B1 (en) 2017-07-05
WO2007048077A3 (en) 2007-07-05
CN101484470A (zh) 2009-07-15
CA2626542A1 (en) 2007-04-26
KR20140133958A (ko) 2014-11-20
DK1945666T3 (da) 2013-07-01
AU2006304886A1 (en) 2007-04-26
ES2642787T3 (es) 2017-11-20
CN103435695A (zh) 2013-12-11
WO2007048077A2 (en) 2007-04-26
US20200255518A1 (en) 2020-08-13
IL218943A0 (en) 2012-05-31
EP2388273A1 (en) 2011-11-23
CA2626542C (en) 2018-07-03
EP2388272A1 (en) 2011-11-23
PL1945666T3 (pl) 2013-09-30
KR20080068089A (ko) 2008-07-22
NZ568433A (en) 2012-07-27
JP2009512694A (ja) 2009-03-26
ES2417147T3 (es) 2013-08-06
AU2006304886B2 (en) 2012-04-12
JP2012250984A (ja) 2012-12-20

Similar Documents

Publication Publication Date Title
CN101484470B (zh) 具有增强的抗体依赖性细胞毒性活性的抗体及其生产方法和用途
JP6433786B2 (ja) 高度ガラクトシル化抗体
TWI856299B (zh) 抗人類vista抗體及其用途
US20130149301A1 (en) Anti-cd137 antibody as an agent in the treatment of inflammatory conditions
EP2399935A2 (en) An anti-CD137 antibody as an agent in the treatment of cancer and glycosylation variants thereof
KR20160003634A (ko) 고도로 갈락토실화된 항-her2 항체 및 이의 용도
US20060182744A1 (en) Anti-CD137 antibody as an agent in the treatment of cancer and glycosylation variants thereof
AU2012201010B2 (en) Antibodies with enhanced antibody-dependent cellular cytoxicity activity, methods of their production and use
AU2015201981A1 (en) Antibodies with enhanced antibody-dependent cellular cytoxicity activity, methods of their production and use
AU2012293420B2 (en) Highly galactosylated antibodies

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: GENZYME CORP.

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20110919

Address after: The American state of Massachusetts

Applicant after: Gtc Biotherapeutics Inc

Co-applicant after: Genzyme Corp

Address before: The American state of Massachusetts

Applicant before: Gtc Biotherapeutics Inc

C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: The American state of Massachusetts

Applicant after: GTC BIOTHERAPEUTICS INC.

Applicant after: Genzyme Corp

Address before: The American state of Massachusetts

Applicant before: Gtc Biotherapeutics Inc

Applicant before: Genzyme Corp

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: GTC BIOTHERAPEUTICS INC. TO: IVO BIOLOGICAL PREPARATION CO., LTD.

C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: LFB AMERICAN LTD.

Free format text: FORMER OWNER: IVO BIOLOGICAL PREPARATION CO., LTD.

Effective date: 20141119

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20141119

Address after: The American state of Massachusetts

Patentee after: LFB USA Ltd

Patentee after: Genzyme Corp

Address before: The American state of Massachusetts

Patentee before: GTC BIOTHERAPEUTICS INC.

Patentee before: Genzyme Corp

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140723

Termination date: 20161023